Literature DB >> 26616038

One versus two doses: What is the best use of vaccine in an influenza pandemic?

Laura Matrajt1, Tom Britton2, M Elizabeth Halloran3, Ira M Longini4.   

Abstract

Avian influenza A (H7N9), emerged in China in April 2013, sparking fears of a new, highly pathogenic, influenza pandemic. In addition, avian influenza A (H5N1) continues to circulate and remains a threat. Currently, influenza H7N9 vaccines are being tested to be stockpiled along with H5N1 vaccines. These vaccines require two doses, 21 days apart, for maximal protection. We developed a mathematical model to evaluate two possible strategies for allocating limited vaccine supplies: a one-dose strategy, where a larger number of people are vaccinated with a single dose, or a two-dose strategy, where half as many people are vaccinated with two doses. We prove that there is a threshold in the level of protection obtained after the first dose, below which vaccinating with two doses results in a lower illness attack rate than with the one-dose strategy; but above the threshold, the one-dose strategy would be better. For reactive vaccination, we show that the optimal use of vaccine depends on several parameters, with the most important one being the level of protection obtained after the first dose. We describe how these vaccine dosing strategies can be integrated into effective pandemic control plans.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Infectious disease modeling; Influenza; Influenza vaccine; Mathematical model

Mesh:

Substances:

Year:  2015        PMID: 26616038      PMCID: PMC4664891          DOI: 10.1016/j.epidem.2015.06.001

Source DB:  PubMed          Journal:  Epidemics        ISSN: 1878-0067            Impact factor:   4.396


  20 in total

1.  Novel avian-origin human influenza A(H7N9) can be transmitted between ferrets via respiratory droplets.

Authors:  Lili Xu; Linlin Bao; Wei Deng; Libo Dong; Hua Zhu; Ting Chen; Qi Lv; Fengdi Li; Jing Yuan; Zhiguang Xiang; Kai Gao; Yanfeng Xu; Lan Huang; Yanhong Li; Jiangning Liu; Yanfeng Yao; Pin Yu; Xiyan Li; Weijuan Huang; Xiang Zhao; Yu Lan; Junfeng Guo; Weidong Yong; Qiang Wei; Honglin Chen; Lianfeng Zhang; Chuan Qin
Journal:  J Infect Dis       Date:  2013-08-29       Impact factor: 5.226

2.  Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9).

Authors:  Michael T Osterholm; Katie S Ballering; Nicholas S Kelley
Journal:  JAMA       Date:  2013-06-26       Impact factor: 56.272

3.  Global concerns regarding novel influenza A (H7N9) virus infections.

Authors:  Timothy M Uyeki; Nancy J Cox
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

Review 4.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Authors:  Michael T Osterholm; Nicholas S Kelley; Alfred Sommer; Edward A Belongia
Journal:  Lancet Infect Dis       Date:  2011-10-25       Impact factor: 25.071

5.  Critical immune and vaccination thresholds for determining multiple influenza epidemic waves.

Authors:  Laura Matrajt; Ira M Longini
Journal:  Epidemics       Date:  2011-12-07       Impact factor: 4.396

6.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

7.  Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus.

Authors:  Martin Linster; Sander van Boheemen; Miranda de Graaf; Eefje J A Schrauwen; Pascal Lexmond; Benjamin Mänz; Theo M Bestebroer; Jan Baumann; Debby van Riel; Guus F Rimmelzwaan; Albert D M E Osterhaus; Mikhail Matrosovich; Ron A M Fouchier; Sander Herfst
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

8.  Modeling malaria vaccines. II: Population effects of stage-specific malaria vaccines dependent on natural boosting.

Authors:  M E Halloran; C J Struchiner; A Spielman
Journal:  Math Biosci       Date:  1989-05       Impact factor: 2.144

9.  Containing pandemic influenza with antiviral agents.

Authors:  Ira M Longini; M Elizabeth Halloran; Azhar Nizam; Yang Yang
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

10.  Tropism and innate host responses of a novel avian influenza A H7N9 virus: an analysis of ex-vivo and in-vitro cultures of the human respiratory tract.

Authors:  Michael C W Chan; Renee W Y Chan; Louisa L Y Chan; Chris K P Mok; Kenrie P Y Hui; Joanne H M Fong; Kin P Tao; Leo L M Poon; John M Nicholls; Y Guan; J S Malik Peiris
Journal:  Lancet Respir Med       Date:  2013-07-25       Impact factor: 30.700

View more
  9 in total

1.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  Seasonality and the effectiveness of mass vaccination.

Authors:  Dennis L Chao; Dobromir T Dimitrov
Journal:  Math Biosci Eng       Date:  2016-04-01       Impact factor: 2.080

3.  Vaccination strategies when vaccines are scarce: on conflicts between reducing the burden and avoiding the evolution of escape mutants.

Authors:  Félix Geoffroy; Arne Traulsen; Hildegard Uecker
Journal:  J R Soc Interface       Date:  2022-06-29       Impact factor: 4.293

4.  Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Authors:  Leora R Feldstein; Laura Matrajt; M Elizabeth Halloran; Wendy A Keitel; Ira M Longini
Journal:  Vaccine       Date:  2016-06-20       Impact factor: 3.641

5.  Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination.

Authors:  Laura Matrajt; Julia Eaton; Tiffany Leung; Dobromir Dimitrov; Joshua T Schiffer; David A Swan; Holly Janes
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 14.919

6.  Optimizing one-dose and two-dose cholera vaccine allocation in outbreak settings: A modeling study.

Authors:  Tiffany Leung; Julia Eaton; Laura Matrajt
Journal:  PLoS Negl Trop Dis       Date:  2022-04-20

7.  Targeted vaccination and the speed of SARS-CoV-2 adaptation.

Authors:  Sylvain Gandon; Sébastien Lion
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-18       Impact factor: 11.205

8.  Challenges of evaluating and modelling vaccination in emerging infectious diseases.

Authors:  Zachary J Madewell; Natalie E Dean; Jesse A Berlin; Paul M Coplan; Kourtney J Davis; Claudio J Struchiner; M Elizabeth Halloran
Journal:  Epidemics       Date:  2021-10-05       Impact factor: 5.324

9.  Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2.

Authors:  Leonardo Souto Ferreira; Otavio Canton; Rafael Lopes Paixão da Silva; Silas Poloni; Vítor Sudbrack; Marcelo Eduardo Borges; Caroline Franco; Flavia Maria Darcie Marquitti; José Cássio de Moraes; Maria Amélia de Sousa Mascena Veras; Roberto André Kraenkel; Renato Mendes Coutinho
Journal:  PLoS Comput Biol       Date:  2022-03-25       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.